298 related articles for article (PubMed ID: 36330617)
21. Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics.
Piplani S; Singh P; Petrovsky N; Winkler DA
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835602
[TBL] [Abstract][Full Text] [Related]
22. Predicting Potential SARS-COV-2 Drugs-In Depth Drug Database Screening Using Deep Neural Network Framework SSnet, Classical Virtual Screening and Docking.
Karki N; Verma N; Trozzi F; Tao P; Kraka E; Zoltowski B
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557253
[TBL] [Abstract][Full Text] [Related]
23. Plant-Derived Antiviral Compounds as Potential Entry Inhibitors against Spike Protein of SARS-CoV-2 Wild-Type and Delta Variant: An Integrative in SilicoApproach.
Ambrose JM; Kullappan M; Patil S; Alzahrani KJ; Banjer HJ; Qashqari FSI; Raj AT; Bhandi S; Veeraraghavan VP; Jayaraman S; Sekar D; Agarwal A; Swapnavahini K; Krishna Mohan S
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335139
[TBL] [Abstract][Full Text] [Related]
24. Discovery of New Hydroxyethylamine Analogs against 3CL
Kumar S; Sharma PP; Shankar U; Kumar D; Joshi SK; Pena L; Durvasula R; Kumar A; Kempaiah P; Poonam ; Rathi B
J Chem Inf Model; 2020 Dec; 60(12):5754-5770. PubMed ID: 32551639
[TBL] [Abstract][Full Text] [Related]
25. Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective.
Abosheasha MA; El-Gowily AH; Elfiky AA
J Thromb Thrombolysis; 2022 Feb; 53(2):273-281. PubMed ID: 34510337
[TBL] [Abstract][Full Text] [Related]
26. Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method.
Jalalvand A; Khatouni SB; Najafi ZB; Fatahinia F; Ismailzadeh N; Farahmand B
J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):85-95. PubMed ID: 34265888
[TBL] [Abstract][Full Text] [Related]
27. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
29. Virtual Screening of Phytochemicals by Targeting HR1 Domain of SARS-CoV-2 S Protein: Molecular Docking, Molecular Dynamics Simulations, and DFT Studies.
Majeed A; Hussain W; Yasmin F; Akhtar A; Rasool N
Biomed Res Int; 2021; 2021():6661191. PubMed ID: 34095308
[TBL] [Abstract][Full Text] [Related]
30. In silico Drug Repurposing for COVID-19: Targeting SARS-CoV-2 Proteins through Docking and Consensus Ranking.
Cavasotto CN; Di Filippo JI
Mol Inform; 2021 Jan; 40(1):e2000115. PubMed ID: 32722864
[TBL] [Abstract][Full Text] [Related]
31. A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2).
Zeng MS; Yu WD; Wang HX; Liu JY; Xu PP
Int J Biol Macromol; 2021 Jul; 183():2248-2261. PubMed ID: 34111482
[TBL] [Abstract][Full Text] [Related]
32. Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics.
Oany AR; Mia M; Pervin T; Junaid M; Hosen SMZ; Moni MA
Int J Antimicrob Agents; 2020 Dec; 56(6):106177. PubMed ID: 32987103
[TBL] [Abstract][Full Text] [Related]
33. Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study.
Ramírez-Salinas GL; Martínez-Archundia M; Correa-Basurto J; García-Machorro J
Molecules; 2020 Nov; 25(23):. PubMed ID: 33260370
[TBL] [Abstract][Full Text] [Related]
34. Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein.
Sun C; Zhang J; Wei J; Zheng X; Zhao X; Fang Z; Xu D; Yuan H; Liu Y
PLoS One; 2021; 16(1):e0245975. PubMed ID: 33493227
[TBL] [Abstract][Full Text] [Related]
35. Exploring Binding Pockets in the Conformational States of the SARS-CoV-2 Spike Trimers for the Screening of Allosteric Inhibitors Using Molecular Simulations and Ensemble-Based Ligand Docking.
Gupta G; Verkhivker G
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732174
[TBL] [Abstract][Full Text] [Related]
36. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
Unni S; Aouti S; Thiyagarajan S; Padmanabhan B
J Biosci; 2020; 45(1):. PubMed ID: 33184246
[TBL] [Abstract][Full Text] [Related]
37. Dual inhibition of SARS-CoV-2 spike and main protease through a repurposed drug, rutin.
Kumari A; Rajput VS; Nagpal P; Kukrety H; Grover S; Grover A
J Biomol Struct Dyn; 2022 Jul; 40(11):4987-4999. PubMed ID: 33357073
[TBL] [Abstract][Full Text] [Related]
38. Phytoconstituents from Moringa oleifera fruits target ACE2 and open spike glycoprotein to combat SARS-CoV-2: An integrative phytochemical and computational approach.
Siddiqui S; Ahmad R; Alaidarous M; Zia Q; Ahmad Mir S; Alshehri B; Srivastava A; Trivedi A
J Food Biochem; 2022 May; 46(5):e14062. PubMed ID: 35043973
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
Jung LS; Gund TM; Narayan M
Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784
[TBL] [Abstract][Full Text] [Related]
40. Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry.
Duarte RRR; Copertino DC; Iñiguez LP; Marston JL; Bram Y; Han Y; Schwartz RE; Chen S; Nixon DF; Powell TR
Mol Med; 2021 Sep; 27(1):105. PubMed ID: 34503440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
